Claims for Patent: 8,425,906

Summary for Patent: 8,425,906

Title:	Method to inhibit cancer targeting CD24
Abstract:	The present invention relates to a method to inhibit cancer by targeting CD24, more precisely a method to inhibit cancer by using CD24 expressed in most cancer cells as a target of an antibody therapeutic agent or by inhibiting the interaction between CD24 and P-selectin. CD24 is over-expressed in most cancer cells and CD24 accumulated in cytoplasm accelerates metastasis. Therefore, the method to inhibit cancer of the invention by targeting CD24 can be effectively used for the treatment of cancer by inhibiting the progress of various cancers over-expressing CD24.
Inventor(s):	Shin; Young Kee (Seoul, KR), Choi; Yoon-La (Seoul, KR), Park; Young Woo (Daejeon-si, KR), Lee; Seung Hyun (Anyang-si, KR), Song; Kyoung (Incheon, KR)
Assignee:	SNU R&DB Foundation (Seoul, KR)
Application Number:	12/307,108
Patent Claims:	1. A method of inhibiting cancer overexpressing CD24, comprising: administering a therapeutically effective amount of an anti-CD24 antibody to a subject having cancer. 2. The method according to claim 1, wherein the antibody specifically recognizes the amino acid sequence of CD24 represented by SEQ. ID. NO: 7. 3. The method according to claim 1, wherein the antibody has complement dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. 4. The method according to claim 1, wherein the cancer overexpressing CD24 is ovarian cancer, breast cancer, small cell lung cancer, prostatic cancer, pancreatic cancer, rectal cancer, bladder cancer, liver cancer, small intestine cancer, large intestine cancer, cervical cancer or cholangiocarcinoma. 5. A method of inhibiting cancer overexpressing CD24, comprising: co-administering a therapeutically effective amount of an anti-CD24 antibody and another anticancer agent to a subject having cancer. 6. The method according to claim 5, wherein another anticancer agent is a chemotherapeutic agent, a radiotherapeutic agent or an immunotherapeutic agent. 7. The method according to claim 6, wherein the chemotherapeutic agent is one or more compounds selected from the group consisting of ifosfamide, doxorubicin HCL, bleomycin, mitomycin, etoposide, vinblastine, vincristine, vinorelbin, paclitaxel, docetaxel, irinotecan, topotecan, hydroxyurea, cyclophosphamide, melphalan, chlorambucil, carmustine, cisplatin, carboplatin, fluorouracil, capecitabine, gemcitabine, imatinib and goserelin acetate. 8. The method according to claim 6, wherein the radiotherapeutic agent is a nuclide emitting one or more radioactive rays selected from the group consisting of x-ray, gamma-ray, electron beam, photon, alpha-particle and neutron. 9. The method according to claim 8, wherein the nuclide is selected from the group consisting I-131, Co-60, Co-57, Ir-192, Ho-166, P-32, V-48, Au-198, Tc-99m, I-125, Dy-165, Re-188, Er-169, Sm-153, Y-90, Pd-109 and Sr-89. 10. The method according to claim 6, wherein the immunotherapeutic agent is a cytokine or an antigen specific therapeutic antibody. 11. The method according to claim 10, wherein the cytokine is one or more compounds selected from the group consisting of interleukin-1 (IL-1), IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-15, IL-18, CSF-GM, CSF-G, IFN-.gamma., IFN-.alpha., TNF, TGF-.beta., FLT-3 ligand and CD40 ligand. 12. The method according to claim 10, wherein the antigen specific therapeutic antibody is selected from the group consisting of Rituxan, Herceptin, Zevalin, Erbitux, Mylotarg, Campath-1H, Zenapax, Remicade and Enbrel. 13. The method according to claim 5, wherein the anti-CD24 antibody has complement dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. 14. The method according to claim 5, wherein the cancer overexpressing CD24 is ovarian cancer, breast cancer, small cell lung cancer, prostatic cancer, pancreatic cancer, rectal cancer, bladder cancer, liver cancer, small intestine cancer, large intestine cancer, cervical cancer or cholangiocarcinoma. 15. The method according to claim 5, wherein the anti-CD24 antibody specifically recognizes the amino acid sequence of CD24 represented by SEQ. ID. NO: 7.

Details for Patent 8,425,906

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2026-06-30
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2026-06-30
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	12/10/1997		2026-06-30